Daunorubicin vs ABV Chemotherapy in HIV-Associated Kaposi's Sarcoma Treatment

This study focuses on treating HIV-associated Kaposi's Sarcoma, a type of cancer that can develop in people with HIV. The research aims to compare the safety and effectiveness of two different treatment options: Daunoxome (daunorubicin liposomal) and a combination chemotherapy known as ABV (Adriamycin/Bleomycin/Vincristine). Both treatments will be used alongside antiretroviral therapy, a standard treatment for HIV. The goal is to understand which treatment option works better and causes fewer side effects, potentially improving care for individuals with this condition. During the study, participants will receive either Daunoxome or ABV, in addition to their regular antiretroviral therapy. The researchers will monitor the severity and time of onset of any side effects from the start of therapy. They will also compare how long the responses to treatment last, the rate of responses, and the time it takes for responses to occur. This will help them understand the benefits and risks of each treatment approach.